Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer - NCBI
Abstract
OBJECTIVE:
To determine the potential economic impact of a paclitaxel drug shortage in patients with newly diagnosed, untreated
ovarian cancer.
RESULTS:
...... A drug shortage that affects approximately 50% of women
initiating chemotherapy is expected to impact 779 women and cost third
party payers an
additional $8,699,872 monthly.
CONCLUSIONS:
Our
model indicates that chemotherapy drug shortages can have a significant
negative impact on the average cost of primary treatment for
ovarian cancer and have the potential to negatively impact health system costs.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.